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3Abstract
Aims: To evaluate the Hypoglycaemia Symptom Rating Questionnaire (HypoSRQ©) 
and relationships between self-reported hypoglycaemia and hypoglycaemia 
measured using blinded continuous glucose monitoring (CGM).
Methods: Diabetes outpatients (n=113) recruited from Ashford and St. Peter’s 
Hospital completed the HypoSRQ (recent weeks version) and provided clinical 
information. Thirty participants used blinded CGM for six days and completed the 
HypoSRQ (24-hour version) for seven days, at the end of each week (7-day version), 
and after four weeks (recent weeks version). 
Results: The HypoSRQ had a single-factor structure and excellent internal 
consistency (α=0.90). There was high correspondence in recalled symptoms, bother 
ratings and hypoglycaemic episodes across one week and four weeks (r=0.84-0.98, 
p<0.001). HypoSRQ-reported hypoglycaemia correlated significantly with CGM-
measured hypoglycaemia (interstitial glucose ≤3.9mmol/l) frequency (r=0.72, 
p<0.001) across six days. The magnitude of the correlation increased when the 
person’s own threshold for detecting hypoglycaemia was used (r=0.78, p<0.001). 
The number of days (out of six) a person reported symptoms of hypoglycaemia was 
associated with the number of days CGM detected hypoglycaemia (interstitial 
glucose <3.9mmol/l) (r=0.83, p<0.001) and remained significant after controlling for 
covariates.
Conclusions: Psychometric properties of the HypoSRQ make it attractive for use in 
people with insulin-treated diabetes. The HypoSRQ may be a less-invasive and 
more-economical alternative to CGM.
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1. Introduction
There are few well-validated hypoglycaemia symptom questionnaires. The 
Edinburgh Hypoglycaemia Symptom Scale (1) records presence and intensity of 
hypoglycaemia symptoms but not how bothersome symptoms are. The Diabetes 
Symptoms Checklist-Revised (DSC-R) (2) contains a three-item factor termed 
‘hypoglycaemic symptoms’ (‘Moodiness’, ‘Irritability just before a meal’, ‘Easily 
irritated or annoyed’). Most hypoglycaemic symptoms are excluded and scale validity 
has been questioned due to lack of expected correlations with hypoglycaemia 
measures (3,4). Improved assessment of hypoglycaemia symptoms is important to 
identify those who are hypoglycaemia unaware, require treatment modification, 
education or other support, and will complement existing self-reported outcome 
measures (5-8). 
Symptoms of hypoglycaemia have been investigated through observations of people 
with diabetes and during experimentally induced hypoglycaemia in individuals 
without diabetes (9). Autonomic symptoms, which are associated with counter-
regulatory hormones and autonomic nervous system activation, include sweating, 
shaking, anxiety, palpitations and nausea (10). Neuroglycopenic symptoms, 
5attributed to glucose deprivation on higher mental functions, include dizziness, 
confusion, speech/coordination difficulties, and tiredness (10). 
Previous studies have categorised hypoglycaemic symptoms using factor analysis 
(11,12), providing compelling evidence for the separation of hypoglycaemic 
symptoms into factors typically labelled autonomic, neuroglycopenic and malaise.  
However, hypoglycaemic symptom profiles are idiosyncratic, varying within and 
between individuals (13,14). For example, patients with Type 1 diabetes mellitus 
(DM) who were asked to record symptoms of each hypoglycaemic episode over 9-12 
months varied substantially in between-episode consistency of symptom reports 
(14). Most research into hypoglycaemia has focused on people with Type 1 DM. 
However it is well-known that individuals with Type 2 DM treated with insulin therapy 
can also experience hypoglycaemia. Results from a systematic review of 
hypoglycaemia in people with Type 2 DM concluded that older patients and those 
with longer duration of diabetes, less insulin reserve, and/or comorbid health 
problems were at increased risk of hypoglycaemia (15). Educating people with Type 
1 and insulin-treated Type 2 DM to identify hypoglycaemia symptoms is therefore 
important. It is likely people who understand their unique symptom profile will be 
better equipped to detect hypoglycaemia and respond appropriately. 
Use of continuous glucose monitoring (CGM) provides a less economical alternative 
to self-reported hypoglycaemia detection in individuals with diabetes. Use of CGM by 
people with diabetes has been associated with improved glycated haemoglobin 
(HbA1c) levels (16). Real-time CGM has also been associated with shorter 
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hypoglycaemic episodes in Type 1 DM (17). However, CGM accuracy is based on 
interstitial-fluid glucose which lags behind blood glucose by 7-15 minutes (18). 
Comparing different CGM devices, mean absolute hypoglycaemia ranged from 10.3-
21.5% (18). CGM accuracy in identifying blood glucose <2.5mmol/l ranged from 
84.4-97.0% (18). These findings suggest CGM has moderate-to-high levels of 
accuracy. To date, there have been no studies which have compared the accuracy 
of CGM-detected hypoglycaemic episodes with the person’s own self-report of 
hypoglycaemia symptoms. In the present study, CGM was used to establish the 
criterion-related validity of the HypoSRQ, and served as the closest we have 
available to a gold standard assessment of hypoglycaemia.
The present study’s objectives were to evaluate the psychometric properties of a 
newly developed measure of hypoglycaemia symptoms, the Hypoglycaemia 
Symptom Rating Questionnaire (HypoSRQ), and to provide preliminary evidence for 
the scale’s validity by comparing, for the first time, the relationship between self-
reported hypoglycaemia, measured by symptom reporting, and physiological 
detection of hypoglycaemia using blinded CGM. 
2. Subjects, Materials and Methods
2.1. Participants 
People with Type 1 or 2 DM, who were on intensive insulin therapy, defined as 
taking at least one basal insulin dose and two or more fast-acting insulin doses per 
day by injection or continuous subcutaneous insulin infusion (CSII) pump, were 
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recruited from diabetes outpatient clinics at Ashford and St. Peter’s NHS Foundation 
Trust, Surrey, UK between January 2011 and May 2012. People were invited to take 
part in the study when they attended one of the diabetes outpatient clinics for a 
routine follow-up appointment. A total of 188 people were given the UK English 
HypoSRQ© (recent weeks version) to complete, along with other questionnaires 
reported elsewhere (19). Participants were free to complete the questionnaires at the 
diabetes clinic or at home and return in a pre-paid envelope. Written informed 
consent was obtained from each participant. A small number of people declined to 
take part after the nature of the study was explained to them. Of those who agreed to 
take part, 113 people (56 men, 57 women) returned a completed questionnaire; a 
60.1% response rate. The questionnaire pack included an ‘opt-in form’ for people to 
complete to indicate their potential interest in using CGM. Blinded CGM was offered 
to individuals on a first-come-first-served basis. Participants who indicated that they 
would be interested in using CGM were contacted by telephone by the researcher to 
discuss this further and to arrange an appointment with the diabetes nurse to have 
the device fitted.   
Thirty participants who were identified by diabetes specialist nurses as having 
experience and awareness of hypoglycaemia volunteered to use blinded CGM for six 
days. The recall period for symptoms in the HypoSRQ can be varied. Participants 
completed the 24-hour version of the HypoSRQ at the end of each of seven days, 
the 7-day version at the end of each of four weeks, and the recent weeks (i.e. about 
the past four weeks) version at endpoint. 
8Participants were aged 18 or older with fluent English. Excluded were individuals 
with a diagnosed learning disability, severe and enduring mental health problems, 
known history of or current alcohol/drug abuse, cognitive impairment, or severe head 
injury. People treated with just one basal insulin injection or with one basal and one 
fast-acting injection per day were excluded from the study. Those who were known 
to clinicians as having hypoglycaemia unawareness were also excluded. 
Wandsworth Local Research Ethics Committee approved the study.
2.2 Hypoglycaemia Symptom Rating Questionnaire (HypoSRQ)
The HypoSRQ was designed for use by people with Type 1 and Type 2 DM who are 
experiencing symptoms of hypoglycaemia. HypoSRQ items were generated 
following a literature review, consultation with a developer of blood-glucose-
awareness training (BGAT) and review of the BGAT manual (20). The manual lists 
commonly experienced symptoms of hypoglycaemia, which were determined 
empirically. BGAT teaches use of symptoms and other cues in detecting high or low 
blood glucose (21). The HypoSRQ format was adapted from a measure of 
hypothyroidism (ThySRQ) (21). Further improvements were introduced following the 
study of optimal formats during the course of interviews with patients who had 
chronic kidney disease to inform the design of the Renal Symptom Rating 
Questionnaire (RenalSRQ; www.healthpsychologresearch.com) . It was established 
during development of the ThySRQ and the RenalSRQ that most existing symptom 
measures were not tapping into how “bothered” a patient is by a particular symptom 
(21). To overcome this problem the -SRQ measures provide a bother scale for rating 
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symptoms experienced, thus dealing with the fact that a symptom may occur 
frequently without bothering the person or may be infrequent but bothersome. 
The UK English HypoSRQ includes seventeen symptom items associated with 
hypoglycaemia and one frequency of hypoglycaemia item. All items are self-
administered and the questionnaire takes approximately five minutes to complete. 
Each item has two parts. Part (a) asks whether or not the symptom has been 
experienced during the time period (e.g. Have you had difficulty concentrating in 
recent weeks?), and part (b) asks how much the symptom has bothered the 
individual (e.g. If yes, how much has this bothered you?) with four response choices: 
‘not at all’, ‘a little’, ‘moderately’ or ‘a lot’ (scoring 1, 2, 3, and 4 respectively). Any 
participants who reported that they did not have a symptom were given a bother 
rating of zero. See Figure 1 for an example item. There are three versions of the 
questionnaire: a past 24-hours version, a past 7-days version, and a recent weeks 
(i.e. about the past four weeks) version. The term “recent-weeks” has been found 
during interviews and questionnaire development work to be interpreted as meaning 
the past 3 to 6 weeks (21). Specifying “i.e. about the past four weeks” helped define 
what was intended by “recent weeks” while showing that we did not expect absolute 
precision. 
The HypoSRQ has been linguistically validated into seven languages for North and 
South America and each language version pilot tested with a clinician and in 
cognitive debriefing interviews with five patients in each country. The UK English 
version of the HypoSRQ was tested in semi-structured cognitive debriefing 
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interviews with 5 people with diabetes in the UK (19, 22). The purpose of the 
interviews was to optimise the wording of symptoms. 
2.3 Physiological and biochemical measures
Body mass index (BMI) was calculated from weight and height (kg/m2). HbA1c 
measurement was carried out in the local laboratory based within Ashford & St 
Peter’s NHS Foundation Trust and obtained from the computer system, with the 
participant’s permission.
2.4 Continuous glucose monitoring
Five Medtronic iPro2 CGM devices were used with Enlite sensors (Medtronic Ltd.). 
The iPro2 is a Professional CGM device designed to provide a complete picture of a 
person’s glucose levels using blinded data. CGM devices were fitted by a diabetes 
specialist nurse. Participants were instructed on the use of CGM, given a log sheet 
to record four capillary blood glucose readings daily (i.e. before breakfast, lunch, 
dinner and bedtime) for retrospective calibration of interstitial glucose readings, and 
information on who to contact if a problem arose. Participants were instructed to 
complete the 24-hour version of the HypoSRQ daily for seven days in the evening 
before bed. An appointment was made for participants to return to the diabetes clinic 
after six days to have the CGM sensor removed by the diabetes nurse. 
CGM traces were examined to identify the frequency of low interstitial glucose (LIG). 
LIG was stratified into episodes of hypoglycaemia ≤3.9mmol/l and the person’s self-
reported blood glucose threshold for detecting hypoglycaemia. LIG ≤3.9mmol/l (70 
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mg/dl) is a commonly reported level of blood glucose used to indicate hypoglycaemia 
(23). A lower cut-off of LIG <2.7 mmol/l (50 mg/dl) was also selected to capture those 
individuals who may not experience symptoms at 3.9 mmol/l (70 mg/dl) (24). In 
addition, the participant’s own level to indicate hypoglycaemia was chosen to control 
for individual variation in the level at which people with diabetes pay attention to their 
low blood glucose levels and experience symptoms of hypoglycaemia. The pre-set 
minimal duration for valid hypoglycaemia was at least 10 minutes. 
2.5 Statistical analyses
Data were analysed using SPSS, version 19 (Chicago, IL, USA). One hundred 
(88.5%) participants provided complete HypoSRQ data. Sample size was based on 
criteria for psychometric analyses (25). Means, standard deviations and frequency 
distributions were computed for each HypoSRQ item. Exploratory factor analysis 
(EFA) and internal consistency reliability analysis (Cronbach’s alpha) were used to 
investigate the scale structure of the HypoSRQ and to guide removal of items. 
Normality of distributions was assessed by histograms and Z (skew) scores. 
HypoSRQ symptom frequency, bother ratings and the number of hypoglycaemic 
episodes reported were positively skewed. Square-root transformations resulted in 
these variables being normally distributed. Independent samples t-tests and chi-
square tests were used to compare those who completed with HypoSRQ 
questionnaire only with those who completed blinded CGM for six days on all 
measured variables. Pearson’s correlation coefficients examined consistency in 
recall of HypoSRQ symptom frequency, bother ratings and number of hypoglycaemic 
episodes over seven days and recent weeks (i.e. about the past four weeks), and the 
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relationships between HypoSRQ scores and blinded CGM-detected hypoglycaemia 
(over six days). Sensitivity and specificity of the HypoSRQ as a tool for detecting 
hypoglycaemia was compared against blinded CGM using the standard cut-off of 
LIG ≤3.9mmol/l. 
3. Results
Table 1 shows characteristics for the whole sample (n=113) and the subset of 
participants who completed blinded CGM for six days (n=30). There were no 
significant differences between participants who used blinded CGM for six days and 
those who completed questionnaires only in any of the variables measured. 
Women reported a significantly greater number of hypoglycaemia symptoms (t(100) 
= -3.91, p < 0.001) and higher HypoSRQ bother ratings (t(100) = -3.47, p < 0.001) 
than men. Age was inversely correlated with the number of HypoSRQ symptoms that 
were reported (r(98) = -0.33, p = 0.001) and HypoSRQ symptom bother ratings (r(98) 
= -0.31, p = 0.002). Younger people also reported more episodes of hypoglycaemia 
than older people (r(78) = 0.34, p < 0.01). There was a small negative correlation 
between body mass index (kg/m2) and HypoSRQ symptom frequency scores (r(90) = 
-0.23, p = 0.03) indicating that people who had a higher body mass index reported
fewer symptoms of hypoglycaemia compared to people with a lower body mass 
index. Older age at leaving full-time education was significantly associated with 
higher HypoSRQ symptom frequency scores (r(57) = 0.32, p = 0.02) and HypoSRQ 
bother rating scores (r(57) = 0.27, p = 0.04). There were no significant differences in 
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HypoSRQ symptom frequency or symptom bother rating scores or the number of 
episodes of hypoglycaemia reported between people with Type 1 and Type 2 DM. 
Glycated haemaglobin (HbA1c), duration of diabetes, and comorbidity were not 
significantly associated with HypoSRQ scores.
Table 2 shows the HypoSRQ symptom frequency and bother ratings for each item. 
Among the 71 participants who reported experiencing hypoglycaemia the mean 
number of episodes was 6.3 (SD=5.8) in recent weeks (i.e. about the past four 
weeks). The mean number of symptoms reported per participant was 6.6 (SD=4.4) 
with 26% reporting that they had experienced 10 or more symptoms in recent weeks.
The HypoSRQ provides space for participants to note symptoms that they 
experienced which had not been mentioned in the questionnaire. Fourteen 
participants responded in this section of the questionnaire. Examination of these 
responses found they were mostly expanding on existing questionnaire items, or 
were referring to symptoms which were more typically indicators of hyperglycaemia 
(i.e. numbness or tingling of mouth or face). Hunger, which was reported by 3 
participants, was the one exception.
3.1 Factor structure
Prior to conducting the main exploratory factor analysis an unforced principal 
components analysis (PCA) was carried out. The unforced PCA included the 17 
HypoSRQ (recent weeks version) symptom items and responses from 100 
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participants with complete data. Output from the PCA was used to check the data to 
ensure suitability for factor analysis. Inspection of the correlation matrix revealed no 
inter-item correlations exceeding r=0.80, thus indicating no problems with 
multicollinearity within the data. The Kaiser-Meyer-Olkin (KMO, measure of sampling 
adequacy) value was 0.831, which was well above the cut-off value of 0.60 (26) and 
Bartlett’s Test of Sphericity (27) reached statistical significance. Initial data checks 
indicated that the properties of the correlation matrix justified a factor analysis being 
carried out. One item, ‘Passed out/Lost consciousness’, was problematic with all 
correlations <0.20 and was removed. After removal of this item the PCA revealed 
four components with eigenvalues greater than 1. However, visual inspection of 
Cattell’s scree plot suggested a single component accounted for the majority of the 
variance. Horn’s parallel analysis (28) also suggested a one component solution. 
The structure of the HypoSRQ was explored using Principal Axis Factoring (PAF) 
with oblique rotation (to allow possible correlation between factors). Initially a forced 
three-factor solution was conducted on the 16 remaining HypoSRQ items to 
determine whether three factors could be distinguished representing groups of 
symptoms: neuroglycopenic, autonomic, and malaise as has previously been 
reported (1). The results revealed a 3-factor structure accounting for 38.96% of the 
variance. Examination of the pattern matrix revealed several items had loadings of 
<0.4 and there was no satisfactory evidence for clear subgroups of symptoms. 
Factor 1 and factor 2 were also moderately correlated (r=0.618) suggesting that they 
could be combined into a single factor. 
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The scree plot indicated there was one clear factor which accounted for the majority 
of the variance. Therefore, a forced one-factor PAF was conducted on the 16 
HypoSRQ items (Table 3). Palpitations and blurred vision were found to have factor 
loadings <0.4 (0.356 and 0.374 respectively). The analyses were repeated after 
excluding these two items (Table 3). All of the remaining 14 items loaded well onto a 
single factor (all  >0·4) and accounted for 31.83% of the variance.
3.2 Internal consistency reliability 
Reliability analysis was initially conducted on all 17 HypoSRQ items. Cronbach’s α 
was strong with an alpha of 0.898 (standardised alpha=0.889). Item-total correlations 
for all items (except passed out/lost consciousness) were well above the minimum 
satisfactory level of 0·2. Excluding passed out/lost consciousness, palpitations and 
blurred vision increased Cronbach’s alpha to 0.905. These findings support the 
results of the PAF which suggested that passed out/lost consciousness, blurred 
vision and palpitations should be omitted from the scale score. 
3.3 HypoSRQ scoring
A HypoSRQ symptom frequency score is obtained by summing the total number of 
14 symptoms reported (range 0–14). A HypoSRQ bother rating score is obtained by 
summing bother ratings for each of the 14 items as follows: 0 ‘did not have the 
symptom’, 1 ‘not at all’, 2 ‘a little’, 3 ‘moderately’, 4 ‘a lot’. Total bother rating scores 
range from 0-56, with higher scores indicating that the person was more bothered by 
their hypoglycaemia symptoms. An additional item records the number of episodes 
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of hypoglycaemia a person has experienced during the time period being assessed 
and a separate bother rating ranging from 0-4. 
3.4 Recall of hypoglycaemia over seven days and recent weeks
The number of participants for individual correlations varied due to missing data (n 
range=21-24). The 7-days version of the HypoSRQ correlated highly with the 24-
hours version of the HypoSRQ summed across seven days: symptom frequency 
(r=0.94, p<0.001), bother ratings (r=0.98, p<0.001), and number of hypoglycaemic 
episodes (r=0.97, p<0.001). These results indicate that people were almost as good 
at recalling hypoglycaemia when asked at the end of seven days as they were when 
asked daily. The recent weeks version of the HypoSRQ was highly correlated with 
the 7-days version of the HypoSRQ summed across four weeks: symptom frequency 
(r=0.91, p<0.001), bother ratings (r= 0.94, p<0.001) and number of hypoglycaemic 
episodes (r=0.84, p<0.001). Recall of hypoglycaemia across four weeks was almost 
as reliable as recall of hypoglycaemia over seven days. 
3.5 Correlations between HypoSRQ and blinded CGM-measured hypoglycaemia
The relationships between HypoSRQ symptom frequency, bother ratings and 
number of hypoglycaemic episodes (summed across six days) and the frequency of 
blinded CGM-measured hypoglycaemia at LIG ≤3.9mmol/l, LIG ≤2.9mmol/l, and at 
the individual’s own threshold for detecting hypoglycaemia (range 1.9-5.0mmol/l) 
were examined among the 30 participants who completed CGM for six days. 
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The number of hypoglycaemic episodes a person reported on the 24-hour version of 
the HypoSRQ (summed across 6 days) was significantly correlated with the 
frequency of blinded CGM-measured hypoglycaemic episodes at LIG ≤3.9mmol/l 
(r=0.72, p<0.001). There was a strong correlation between self-reported frequency of 
hypoglycaemia and blinded CGM-measured hypoglycaemic episodes when the 
person’s own threshold for detecting hypoglycaemia was used (r=0.78, p<0.001). 
These correlations remained significant after adjustment for age, sex, insulin 
treatment duration, and type of diabetes (r=0.55, p=0.004, and r=0.68, p=0.002, 
respectively). The relationship between self-reported frequency of hypoglycaemia 
and blinded CGM-measured hypoglycaemia at the lower threshold of LIG ≤2.7mmol/l 
was non-significant (r=0.36, p=0.11). There was a strong significant association 
between the number of days (out of six) an individual reported having one or more 
symptoms of hypoglycaemia and the number of days (out of six) blinded CGM 
detected one or more hypoglycaemic episodes (r=0.83, p<0.001) using the 
3.9mmol/l cut-off. The result was not changed when a partial correlation was used to 
adjust for age, sex, insulin treatment duration and type of diabetes(r=0.83, p<0.001). 
The number of symptoms a person reported and how bothered they were by their 
symptoms did not correlate significantly with blinded CGM-measured frequency of 
hypoglycaemic episodes over six days at LIG <3.9mmol/l, LIG ≤2.7 mmol/l, or using 
the person’s own threshold for detecting hypoglycaemia. 
3.6 Sensitivity and specificity of the HypoSRQ
Of the 30 participants who completed blinded CGM for six days, 24 people 
experienced at least one blinded CGM-measured hypoglycaemic episode. There 
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were 86 hypoglycaemic episodes in total using the 3.9mmol/l cut off level. Of these, 
53 episodes were identified by participants reporting one or more symptoms on the 
HypoSRQ (‘true positives’); therefore the sensitivity of the HypoSRQ in detecting 
blinded CGM-measured hypoglycaemia using symptoms alone was 60.9% (95% CI 
49.9-71.2) in this sample. Specificity refers to the proportion of occasions when 
blinded CGM showed no hypoglycaemia which was confirmed by no symptoms 
being reported. The HypoSRQ had lower levels of specificity (51.8%; 95% CI 38.0-
65.3). There were 35 occasions when participants did not report any symptoms of 
hypoglycaemia and no hypoglycaemic episodes were detected using blinded CGM 
(‘true negatives’). There were 33 occasions when participants reported one or more 
symptoms of hypoglycaemia in the absence of blinded CGM-detected 
hypoglycaemia (these would typically be known as ‘false positives’ if blinded CGM 
could be relied upon to be an accurate measure of hypoglycaemia). Similarly, there 
were 34 occasions when participants did not report any symptoms of hypoglycaemia 
but blinded CGM-measured hypoglycaemia was detected (‘false negatives’).
The sensitivity and specificity of the HypoSRQ was examined separately for people 
with Type 1 and Type 2 DM. For people with Type 1 DM (n=21), there were 60 
blinded CGM detected hypoglycaemic episodes in total using the 3.9mmol/l cut off 
level over 6 days. Of these, 38 episodes were identified by participants reporting one 
or more symptoms on the HypoSRQ (‘true positives’); therefore the sensitivity of the 
HypoSRQ was 67.9% (95% CI 53.9-79.3) among people with Type 1 DM. Specificity 
(i.e. the proportion of occasions [n=19] when blinded CGM showed no 
hypoglycaemia which was confirmed by no symptoms being reported on the 
HypoSRQ) was 46.3% (95% CI 30.9-62.3). 
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For people with Type 2 DM (n=9), there were 17 blinded CGM detected 
hypoglycaemic episodes in total using the 3.9mmol/l cut off level over 6 days. Of 
these, 12 episodes were identified by participants reporting one or more symptoms 
on the HypoSRQ. The sensitivity of the HypoSRQ to detect CGM-measured 
hypoglycaemia was 70.5 (95% CI 44.0-88.6) among people with Type 2 DM. 
Specificity (i.e. the proportion of occasions when blinded CGM showed no 
hypoglycaemia which was confirmed by no symptoms being reported on the 
HypoSRQ [n=22]) was 40.5% (95% CI 25.1-57.8). 
4. Discussion
The HypoSRQ has a single-factor structure and excellent internal consistency. The 
HypoSRQ in the different versions, covering different time frames, reliably measures 
self-reported hypoglycaemia symptoms, bother ratings, and hypoglycaemic episodes 
over seven days and recent weeks (i.e. about the past four weeks) . The ability of 
people with diabetes to recall hypoglycaemic episodes and symptoms is not well 
documented. In one study recall of severe hypoglycaemia was well-preserved over 
one year among people with Type 1 DM (29). Similar results were found for people 
with Type 2 DM (30). In another study, recall of mild hypoglycaemia was unreliable 
after one week in people with Type 1 DM (31). These studies relied on subjective 
recall of the frequency of hypoglycaemia, which does not take account of symptom 
awareness. The HypoSRQ provides a more comprehensive assessment for use in 
future studies aiming to assess recall and awareness of hypoglycaemia symptoms.
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Associations found between the number of hypoglycaemic episodes reported across 
six days and blinded CGM-measured hypoglycaemia frequency (using the 3.9mmol/l 
cut-off and the participants’ self-reported threshold for detecting hypoglycaemia) 
provides preliminary support for the construct validity of the HypoSRQ. There was 
high correspondence between the number of days (out of six) hypoglycaemia 
symptoms were reported and the number of days on which blinded CGM indicated 
hypoglycaemia. The HypoSRQ, with its comprehensive list of 17 possible symptoms 
(including three items not included in the scale score), may help people recognise 
warning symptoms of personal relevance and take action to prevent a severe 
hypoglycaemic episode. 
In previous research, people with one to three reliable warning symptoms correctly 
identified half of their hypoglycaemic episodes, while those with four or more 
symptoms correctly recognised over 70% of episodes (13). Using the HypoSRQ, 
60.9% of blinded CGM-measured hypoglycaemic episodes were identified using one 
or more symptoms reported by participants. There were also ‘false positives’ 
(hypoglycaemia symptoms in the absence of blinded CGM-detected hypoglycaemia), 
and ‘false negatives’ (blinded CGM-detected hypoglycaemia in the absence of 
symptoms). It is likely some people detected hypoglycaemia CGM did not identify 
leading to ‘false positives’, which might actually be ‘false negatives’ for CGM if the 
HypoSRQ recorded hypoglycaemia CGM failed to detect. Concern has been 
expressed about the accuracy of CGM, particularly at lower interstitial glucose levels 
(32), due to the physiological delay between blood glucose and interstitial glucose, 
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which is greater when blood glucose is falling rapidly (33). This may partly explain 
why associations between the HypoSRQ and blinded CGM were not significant at 
LIG ≤2.7mmol/l in the present study. There have been significant improvements in 
the analytical performance, reliability, and usability of the CGM systems in recent 
years (34) leading to evidence of improved accuracy within the hypoglycaemic range 
(35). However, even the more recent CGM systems continue to have weaknesses in 
detecting hypoglycaemia. Although CGM is promising technology it is not yet 
a sufficiently gold standard measure that can be relied upon in the face of 
contradictory self-report. 
Recognition of hypoglycaemia is not a simple reflection of biological events (13,36). 
For people to use symptoms to recognise hypoglycaemia they must be able to detect 
and interpret symptoms. Several modifiers interfere with these processes including 
antecedent hypoglycaemia, alcohol consumption, and activity. Psychological factors 
play a pivotal role in diabetes self-management decisions, appraisals of risk of 
severe hypoglycaemia, and response to low blood glucose (36). These factors add 
to the variability in frequency of symptoms reported and the extent to which a person 
is bothered by them. Understanding the mechanisms through which modifiers and 
psychological factors interfere with recognition of symptoms of hypoglycaemia 
warrants further investigation. 
The present study had some limitations. Awareness of hypoglycaemia was not 
measured. Without this it is not possible to say for certain whether participants were 
unaware of ‘true’ hypoglycaemia or whether blinded CGM was detecting non-
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significant dips in interstitial glucose. It was not possible to be certain participants 
completed the questionnaires as instructed during the blinded CGM monitoring 
period. Recording times automatically using electronic questionnaires would provide 
a more reliable way of matching self-reported hypoglycaemia with episodes of 
blinded CGM-measured hypoglycaemia. 
Although hunger has been associated with hypoglycaemia in previous literature (37) 
it was not included in the original version of the HypoSRQ because it was expected 
this would occur frequently for most people before meals. In the present study only 
three participants mentioned this symptom in the free response section of the 
questionnaire suggesting it may not be so common among people with diabetes. 
Further work is needed to determine whether hunger is in fact a reliable symptom in 
the detection of hypoglycaemia. If so, there may be a case for inclusion of a hunger 
item in the HypoSRQ and this will be evaluated in future work with the HypoSRQ.
Associations between self-reported hypoglycaemia symptoms and blinded CGM-
estimated hypoglycaemia suggest that the HypoSRQ may be a less-invasive and 
more-economical alternative to CGM, specifically with regard to identifying people 
who may be having difficulty with hypoglycaemia. Further work is needed to establish 
whether the HypoSRQ has value in identifying and monitoring hypoglycaemia among 
people with non-insulin dependent diabetes. The frequency of hypoglycaemia among 
patients with type 2 DM on oral agents alone is generally lower than among those 
treated with insulin. Non-insulin dependent Type 2 DM may confer greater protection 
against hypoglycaemia because the counter-regulatory responses commence at a 
23
higher blood glucose level than in non-diabetic populations and people with type 1 
DM (38). 
The psychometric properties and the associations found between the HypoSRQ and 
blinded CGM-measured hypoglycaemia, make it an attractive measure for future 
research and clinical practice. Further research is needed to increase understanding 
of factors leading to changes in the frequency of different symptoms. The HypoSRQ 
will be useful in helping people to recognise and track changes in awareness of 
hypoglycaemia symptoms over time. Further validation and use of the HypoSRQ in 
different centres is recommended. 
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Have you had palpitations (rapid or strong heart beat) in recent weeks?
No If no, go to next symptom
Yes If yes, complete part (b)
    (b) If yes, how much have these bothered you?
           
        not at all                     a little                 moderately                a lot
Have you … (symptom) … in recent weeks?
1. … had palpitations …
2. …felt dizzy, light-headed or faint …
3. … passed out / lost consciousness …
4. … had difficulty concentrating …
5. … had difficulty thinking quickly and clearly …
6. … felt unusually tired, weak or lethargic …
7. … felt sick or vomited …
8. … had any headaches …
9. … felt unsteady or uncoordinated …
10. … had trembling …
11. … felt suddenly irritable or angry …
12. … felt unusually emotional …
13. … had excessive sweating …
14. … suddenly felt too hot or cold all over, or in part of your body …
15. … felt excessively sleepy …
16. … had blurred vision …
17. … had slurred speech or difficulty taking …
18. … experienced any hypos…
Figure 1: Example of a HypoSRQ item and an abbreviated form of the 18 items. 
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Full sample (N=113) CGM sample (N=30)
  N Range Mean (SD) N Range Mean (SD) p-value
 
Age (yrs.)             113 18-86 48.0 (17.4)            30 20-85 48.1 (17.0) 0.67
Ratio of men to women 56:57         14:16 0.61
Age left full-time education (yrs.)   65 14-32 18.5 (3.4) 20 15-24 17.0 (2.2) 0.07
Currently in full-time education    9  1 0.34
Glycated Haemaglobin (HbA1c)   83  6.1-17.1   8.9 (2.0) 26  6.2-15.8   8.9 (2.2) 0.73
Body Mass Index (kg/m2)   97 17.3-43.8 28.2 (5.8) 26 18.0-41.2 27.8 (5.5) 0.94
Type 1 diabetes (n = 77)
Years since diagnosis   68 1-48 19.5 (12.9) 21 1-42 16.9 (13.6) 0.95
Years on insulin therapy   68 1-48 19.5 (12.9) 21 1-42 16.9 (13.6) 0.82
Number of injections per day   61 3-6   4.3 (0.9) 21 3-6   4.0 (0.8) 0.38
Insulin-treated   71 21
    Plus oral agents     0   0
    Insulin delivered by CSII pump*   12   3
Number of hypoglycaemic episodes    61 0-30   4.9 (6.1) 20 0-20   6.2 (5.7) 0.54
in recent weeks** 
Type 2 diabetes (n = 36)
Years since diagnosis   34 1-40 14.9 (9.3)   9 3-30 12.8 (9.2) 0.41
Years on insulin therapy   32 0.1-39   9.2 (8.6)   9 0.1-12   6.2 (4.3) 0.18
Number of injections per day   35 2-5   3.9 (1.0)   9 2-5   3.9 (0.9) 0.87
Insulin-treated   36   9
    Plus oral agents   21   6
    Insulin delivered by CSII pump*     1   0
Number of hypoglycaemic episodes   30 0-12   2.3 (3.1)   6 0-10    3.0 (4.0) 0.61
in recent weeks**
*CSII, Continuous Subcutaneous Insulin Infusion. Ns vary due to non-applicability and missing data. ** Recent weeks i.e. about the past four weeks.
In the full sample the following co-morbid conditions were reported (n=50): thyroid dysfunction, high blood pressure, high cholesterol, atrial fibrillation, Meniere’s disease, 
epilepsy, depression, urticaria, arthritis, coeliac disease, polycystic ovaries, asthma, Addison’s disease, sciatica, and diverticulitis. Several people had multiple co-morbid 
conditions. Diabetes complications were reported including diabetes-related eye disease (23), renal problems (8), heart problems (6), circulatory problems (5), foot problems 
(14), and neuropathy (8).    
P-values were calculated using independent samples t-tests for continuous variables and chi-sqaure tests for categorical variables.
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Table 1: Characteristics of the study participants.
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 Symptom bother rating
Symptom*    Not at all         A little     Moderately    A lot Mean (SD) [Range used]
    N/%**
(1) (2) (3) (4)
1. Palpitations     31 4 17 7 3 2.29 (0.82) [1-4]
2. Dizzy, light-headed and faint     43 1 24 14 4 2.49 (0.70) [1-4]
3. Passed out/lost consciousness     1 0 0 0 1 4.00 (0.00) [4]     
4. Difficulty concentrating     45 3 20 16 6 2.56 (0.81) [1-4]
5. Difficultly thinking quickly and clearly     47 4 24 14 5 2.43 (0.80) [1-4]
6. Tired, weak or lethargic     63 3 15 26 19 2.97 (0.86) [1-4]
7. Felt sick or vomited     17 1 7 4 5 2.76 (0.97) [1-4]
8. Headaches     48 6 19 11 12 2.60 (1.01) [1-4]
9. Unsteady or uncoordinated     35 2 17 14 2 2.46 (0.70) [1-4]
10. Trembling     45 7 20 12 6 2.38 (0.91) [1-4]
11. Suddenly irritable or angry     51 0 21 18 12 2.82 (0.79) [2-4]
12. Unusually emotional     48 4 19 11 14 2.73 (0.98) [1-4]
13. Excessive sweating     48 2 16 18 12 2.83 (0.86) [1-4]
14. Suddenly too hot or cold     45 2 24 12 7 2.53 (0.82) [1-4]
15. Excessively sleepy     51 3 15 14 19 2.96 (0.96) [1-4]
16. Blurred vision     26 2 9 7 8 2.81 (0.98) [1-4] 
17. Slurred speech or difficulty talking     14 0 9 4 1 2.43 (0.65) [2-4]
18. Recent hypoglycaemia     71 5 35 24 7 2.46 (0.77) [1-4)
* Symptom experienced in recent weeks (i.e. about the past four weeks)
** N=100 participants who provided complete HypoSRQ data
HypoSRQ, Hypoglycaemia Symptom Rating Questionnaire; SD, standard deviation
The HypoSRQ is available via www.healthpsychologyresearch.com. 
The mean and range reported are bother ratings of those who said they had experienced the symptom. The possible range is 1-4 (Not at all – A lot).
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Table 2: HypoSRQ symptom and bother rating frequencies, means (standard deviations) and ranges used for each of the 17 original symptom 
items and recent hypoglycaemia (N=100**).
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                                          Pattern Matrix Coefficients
 Unforced PCA Forced 3-factor                          Forced 1-factor
     (55.06%)      (37.57%)                                      
            
  1   2   3   4   1   2 3             16-items 14-items    
HypoSRQ item    (29.53%)              (31.84%)
 
1:   Palpitations .22 -.03       .17        .76 .30 .15      -.11 .36 item omitted
2:   Dizzy, light-headed or faint .52 -.11       .02        .23 .42 .08  .07 .49 .49
3:   Passed out/lost consciousness                     item omitted item omitted item omitted item omitted
4:   Difficulty concentrating .84 -.04 -.09       .06 .85      -.17  .09 .66 .66
5:   Difficulty thinking quickly and clearly .74 -.20 -.07      -.12 .62      -.07  .27 .63 .65
6:   Tired, weak and lethargic .23  .10  .58  .20 .26 .51       -.12 .62 .61
7:   Felt sick or vomited .22        -.15  .41       -.41 .12 .32  .27 .52 .52
8:   Headaches .64  .07  .05   .01 .48 .10  .03 .54 .54
9:   Unsteady or uncoordinated .27 -.39  .28  -.02 .25 .21  .32 .57 .57
10: Trembling .13 -.22  .53        .14 .14 .45  .16 .60 .59
11: Suddenly irritable or angry .73 -.01  .07   .01 .65 .08  .06 .69 .70
12: Unusually emotional .59  .54        .27       -.08 .45 .26        -.29 .49 .49
13: Excessive sweating             .12 -.64   .20       .11 .15 .17         .39 .46 .47
14: Too hot or cold            -.02 -.12   .73       .07            -.01 .65         .09 .59 .58
15: Excessively sleepy            -.13 -.09   .85   .07            -.13 .79         .07 .57 .57
16: Blurred vision  .01  .22         .61     -.22 .07 .37 -.02 .37 item omitted
17: Slurred speech or difficulty talking .24 -.54   .05      -.39             .09 .10  .46 .38 .40
* Figures in brackets are proportion of cumulative variance explained
HypoSRQ, Hypoglycaemia Symptom Rating Questionnaire. PCA; Principle Components Analysis; PAF, Principal Axis Factoring
Cell entries marked in bold refer to loadings >0.40.
Table 3: Pattern matrix coefficients for exploratory PCA (unforced) and confirmatory PAF (forced three factor and one factor analyses) with oblique rotation of the 
HypoSRQ recent weeks (i.e. about the past four weeks) version.
